Quick Answer
GOLDENWELL BIOTECH, INC. reported Revenue (ASC 606) of $2.3 thousand for fiscal year 2023.
GOLDENWELL BIOTECH, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $2.3K | -95.1% |
| 2022 | $47.8K | +199.4% |
| 2021 | $16.0K | — |
| 2020 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2024 | $139.00 | -49.6% | -12.0% |
| March 31, 2024 | $158.00 | -88.9% | -58.6% |
| September 30, 2023 | $382.00 | -99.1% | +38.4% |
| June 30, 2023 | $276.00 | -92.6% | -80.6% |
| March 31, 2023 | $1.4K | +258.2% | -96.7% |
| September 30, 2022 | $43.7K | +259.1% | +1076.7% |
| June 30, 2022 | $3.7K | +235.7% | +835.3% |
- GOLDENWELL BIOTECH, INC. showed a decrease of -95.1% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from GOLDENWELL BIOTECH, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 12, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: